

## 9-Nor-9-hydroxyhexahydrocannabinols. Synthesis, Some Behavioral and Analgesic Properties, and Comparison with the Tetrahydrocannabinols<sup>1,2</sup>

Raymond S. Wilson,\* Everette L. May,

Laboratory of Chemistry, National Institute of Arthritis, Metabolism, and Digestive Diseases, National Institutes of Health, Bethesda, Maryland 20014

Billy R. Martin, and William L. Dewey

Department of Pharmacology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia 23298.

Received August 25, 1975

The racemic mixture and levo isomer of both 9-nor-9 $\alpha$ -hydroxyhexahydrocannabinol and its 9 $\beta$ -hydroxy isomer were prepared. Both  $\alpha$ - and  $\beta$ -hydroxy compounds were active in the dog ataxia test and depressed spontaneous activity in mice. However, only the  $\beta$ -hydroxy compound was an analgesic in mice with morphine-like potency. The behavioral and analgesic properties of these compounds may be mediated through different sites or mechanisms and may, therefore, be separable.

In an effort to find biologically active synthetic compounds based on the cannabinoid-type structure, we have prepared and tested the 9-nor-9-hydroxyhexahydrocannabinols (9–12, Scheme I). Whereas it is obvious that these compounds are structurally similar to the tetrahydrocannabinols (THC's) from marijuana (Chart I), they are intended to even more closely approximate the potent biologically active metabolites of the THC's, the 11-hydroxy-THC's.<sup>3</sup> Synthetic compounds 9–12 lack only the  $\Delta^8$  or  $\Delta^9$  double bond and the 11-methylene of the 11-hydroxy-THC's. In addition, by comparing axial vs. equatorial hydroxyls at the 9 position in these synthetic compounds, we have found that certain cannabinoid-like biological effects can be readily separated from other effects. The synthesis, analgesic properties in mice, some behavioral effects in dogs and mice, and comparison of these effects with the naturally occurring THC's are herein described.

**Chemistry.** We have previously described the synthesis of 9-nor-9-hydroxyhexahydrocannabinol both as the racemic mixture 7<sup>4</sup> and as the levo mixture 8<sup>5</sup> of diastereomers. Either 7 or 8 was obtained in essentially quantitative yield by sodium borohydride reduction respectively of the racemic 5<sup>4</sup> or levo 6<sup>5</sup> ketone, 9-nor-9-oxohexahydrocannabinol (Scheme I).


Gas chromatographic analysis of the products from the sodium borohydride reduction indicated that the ratio of equatorial hydroxy compound (9 or 10) to axial hydroxy compound (11 or 12) was about 93:7. The stereochemistry of the hydroxyl groups was assigned on the basis of the relative peak half-widths of the C-9 protons in the 100-MHz NMR spectra. In compounds 9 and 10 the peak half-width was twice as large as that observed in 11 and 12, consistent with an axial C-9 proton in the former two compounds and an equatorial C-9 proton in the latter two. The reason for the specificity in this reduction is not readily apparent from examination of molecular models.

Potassium tri-*sec*-butyl borohydride has been reported to give nearly quantitative yields of axial alcohol resulting from equatorial attack on rigid cyclohexanones.<sup>6</sup> Reduction of 5 with this reagent was very selective, giving greater than 98% axial alcohol 11 and less than 2% equatorial alcohol 9 as determined by GC analysis. This provided selective syntheses of both the axial (11 and 12) and equatorial (9 and 10) alcohols. The racemic compounds, 9 and 11, were readily purified by recrystallization, whereas the levo compounds, 10 and 12, were glassy solids which required chromatographic purification.


### Results

The effects of these compounds on the overt behavior of dogs are shown in Table I. As indicated,  $\Delta^9$ -THC is

Chart I



Scheme I



more potent than  $\Delta^8$ -THC and 11-hydroxy- $\Delta^9$ -THC is more potent than  $\Delta^9$ -THC. The synthetic levo-9 $\beta$ -hydroxy compound 10 and the racemic mixture 9 were approximately equipotent with 11-hydroxy- $\Delta^9$ -THC. Based on the results from two dogs racemic 9 $\alpha$ -hydroxy compound 11 appeared to be about one-fifth as potent as 9 and 10.

Mouse-activity-cage data are shown in Table II for both mice tested 10 min and those tested 90 min after injection. At 10 min both *levo*-9 $\beta$ -hydroxy compound 10 and *rac*-9 $\alpha$ -hydroxy compound 11 significantly depressed spontaneous activity. Similar to the above results in dogs, 11 was approximately one-fourth as potent as 10 based on the relative doses to decrease spontaneous activity by one-half. At 90 min both  $\Delta^8$ - and  $\Delta^9$ -THC caused significant depression of spontaneous activity, in agreement with previous results.<sup>7</sup> Compound 10 was also tested at 90 min

**Table I.** Effect of Cannabinoids and Synthetic Compounds on Overt Behavior in Dogs<sup>a</sup>

Dose, mg/kg	$\Delta^8$ -THC	$\Delta^9$ -THC	11-Hydroxy- $\Delta^9$ -THC	9	10	11
0.01			2 (2)			
0.05			4 (2)		1+ (3)	
0.10	0 (1) <sup>b</sup>	0 (1)	2+ (2)	3 (2)	3 (3)	
0.20	0 (1)	3+ (2)				
0.40	2 (2)	4 (2)				
0.50					5+ (2)	3- (2)
1.00	5+ (2)					

<sup>a</sup> Semiquantitated by the dog static-ataxia rating scale (see Pharmacological Methods and ref 7). <sup>b</sup> The mean score of all animals tested is presented with the number of animals tested in parentheses.

**Table II.** Effect of Cannabinoids and Synthetic Compounds on Spontaneous Activity of Mice<sup>a</sup>

Dose, mg/kg	At 10 min postinjection <sup>b</sup>		At 90 min postinjection <sup>c</sup>		
	10	11	$\Delta^8$ -THC	$\Delta^9$ -THC	10
0	104 ± 13	146 ± 17	121 ± 14	181 ± 22	94 ± 19
2.5	102 ± 27	139 ± 17	49 ± 13 <sup>d</sup>	64 ± 19 <sup>d</sup>	41 ± 14 <sup>e</sup>
5.0	50 ± 12 <sup>d</sup>	135 ± 17	84 ± 37	58 ± 20 <sup>f</sup>	38 ± 11 <sup>e</sup>
10.0	23 ± 5 <sup>f</sup>	187 ± 23	28 ± 6 <sup>f</sup>	87 ± 31 <sup>e</sup>	50 ± 18
20.0	38 ± 8 <sup>f</sup>	73 ± 10 <sup>d</sup>	139 ± 56	84 ± 26 <sup>e</sup>	15 ± 6 <sup>f</sup>

<sup>a</sup> Number of interruptions of photocell (mean ± SE) per 15-min period beginning at designated time (see ref 7 for methodology). <sup>b</sup> Vehicle group had an *n* of 16; drug groups had an *n* of 8. <sup>c</sup> Vehicle group had an *n* of 12; drug groups had an *n* of 6. <sup>d</sup> Statistical difference from vehicle was determined by Student's *t* test (*p* < 0.01). <sup>e</sup> *p* < 0.05. <sup>f</sup> *p* < 0.001.

**Table III.** Analgesic Data

Compound	Analgesic ED <sub>50</sub> , mg/kg <sup>a</sup>	
	Hot-plate	Nilsen
9	2.9 (2.3-3.6)	6.0 (4.4-8.3)
10	1.6 (1.3-1.8)	
12	N.A. <sup>b</sup>	
Morphine HCl	1.2 (0.9-1.3)	0.8 (0.6-1.2)
11-Hydroxy- $\Delta^8$ -THC	1.9 (1.4-2.7)	5.4 (3.2-8.9)

<sup>a</sup> 95% confidence limits are shown in parentheses.

<sup>b</sup> Not active at 50 mg/kg.

and found to produce a significant decrease in spontaneous activity.

The results of analgesic testing of 9, 10, and 12 are shown in Table III along with previously tested 11-hydroxy- $\Delta^8$ -THC<sup>5</sup> and morphine. In the hot-plate test, 10 was approximately equipotent with morphine and 11-hydroxy- $\Delta^9$ -THC and about twice as potent as racemic compound 9. Compound 9 and 11-hydroxy- $\Delta^9$ -THC were both slightly less active than morphine in the Nilsen test. Compound 12 was inactive in the hot-plate test at 50 mg/kg.

## Discussion

The 9-nor-9-hydroxyhexahydrocannabinols have potent cannabinoid-like activity in both dogs and mice. In the dog, 9 $\beta$ -hydroxy compounds 9 and 10 were approximately equipotent with 11-hydroxy- $\Delta^9$ -THC. The quantitation of effect in this test is not sufficient to allow distinction between the activities of levo isomer 10 and racemic 9. Generally the levo isomers of the THC's are much more active than their enantiomers.<sup>5,8</sup> Therefore, the levo isomers should be about twice as potent as their racemic counterparts and this appears to be true for the analgesic properties of 9 and 10 as well (vide infra). However, the dog ataxia test is qualitatively useful in predicting which agents have cannabinoid properties in man.

All of the synthetic and natural cannabinoids tested depressed the spontaneous activity of mice. The activity of the THC's at 10 min is not as definitive as that for the synthetic compounds. Previously we have reported a depression of activity by  $\Delta^8$ -THC and little or no effect due to  $\Delta^9$ -THC at 10 min.<sup>7</sup> However, on other occasions

we have even observed a stimulation of activity produced by  $\Delta^9$ -THC at 10 min. Because the response to the THC's is more consistent at 90 min, this would appear to be a more valid time interval during which to conduct the test.

Regarding the slightly greater potency of the  $\beta$ -hydroxy compound over the  $\alpha$ -hydroxy isomer in these behavioral tests, a similar observation was made previously.<sup>9</sup> Mechoulam found that the 9 $\beta$ -methyl isomer of hexahydrocannabinol was more potent than the 9 $\alpha$  isomer in behavioral tests in monkeys.<sup>10</sup> Therefore, based on these limited examples, it appears that for hexahydrocannabinols greater potency is achieved when a single-bonded 9-substituent lies essentially in the plane of the cyclohexane ring as opposed to being oriented below the ring.

The 9 $\beta$ -hydroxy compounds have good analgesic activity in mice in the two tests employed while the 9 $\alpha$ -hydroxy compounds were inactive at considerably higher doses. The *levo*-9 $\beta$ -hydroxy isomer 10 was approximately twice as potent as the racemic mixture 9, suggesting that only the *levo* isomer is active. Compound 10 was essentially equipotent with morphine and 11-hydroxy- $\Delta^9$ -THC in the hot-plate test and slightly less active than morphine in the Nilsen test. If these synthetic cannabinoids lack addiction liability, they may be useful as a novel class of potent analgesics.

A final point of interest is that the 9 $\alpha$ - and 9 $\beta$ -hydroxy compounds produce similar behavioral effects in dogs and mice within about a four- or fivefold potency range, but only the 9 $\beta$ -hydroxy compounds are potent analgesics in mice. Therefore, it would appear that the analgesic and behavioral effects are produced through different sites or different mechanisms and these activities may be completely separable. A more thorough pharmacological evaluation of these compounds will be reported elsewhere.<sup>11</sup>

## Experimental Section

The assigned structures of all compounds reported in this paper were supported by their NMR, ir, and mass spectra. Spectral and elemental analyses were performed by the Section on Analytical Services and Instrumentation of this Laboratory (NIH). Where analyses are indicated only by symbols of the elements, analytical results obtained for these elements were within  $\pm 0.4\%$  of the theoretical values. All melting points were taken on a

Thomas-Hoover melting point apparatus and are uncorrected. Gas chromatographic determinations were performed on a Beckman GC-55 at 230° using a 6-ft 5% XE-60 on Gas Chrom Q glass column. Potassium tri-*sec*-butyl borohydride was purchased as K Selectride (0.5 M in THF) from the Aldrich Chemical Co.

**Pharmacological Methods.** Cannabinoids produce a very characteristic effect on the overt behavior of dogs including static ataxia, hyperreflexia, and decreased spontaneous activity. The effects of the compounds reported in this paper were semi-quantitated in dogs using the methodology and behavioral rating scale reported elsewhere.<sup>7</sup> Briefly, three independent observers rated the effect of each dose of the drug on each dog iv administration using a scale of zero (no effect) to six (dog lies prostrate on floor), and the mean of their scores was recorded. The score at the time of peak activity is reported.

Effects on spontaneous activity in albino mice (Swiss-Webster, 20–25 g) were determined for these compounds using a procedure described previously.<sup>7</sup> Drugs were given ip and then the mice were placed in a photocell activity chamber. Interruptions of the photocell were recorded for 15 min at 10 and 90 min after injection.

Analgesic properties were determined in mice by the hot-plate<sup>12</sup> and Nilsen<sup>13</sup> tests using the methodology described in the references.

All compounds were given as a suspension in Emulphor (EL-620), ethanol, and saline.<sup>14</sup>

(±)-9-Nor-9β-hydroxyhexahydrocannabinol (9). To 0.6 g (0.002 mol) of ketone 5 in 20 ml of MeOH was carefully added 0.288 g (0.008 mol) of NaBH<sub>4</sub>. After stirring for 30 min 10 ml of H<sub>2</sub>O was added and the mixture evaporated to dryness. The residue was taken up in Et<sub>2</sub>O–H<sub>2</sub>O and the Et<sub>2</sub>O layer washed with 5% HCl and brine and dried (Na<sub>2</sub>SO<sub>4</sub>). Evaporation gave a white solid, 0.6 g (100%). Examination of this solid by GC indicated that the mixture was about 95% of 9 and 8% of 11. Recrystallization of the solid from Et<sub>2</sub>O–ligroine gave pure 9, mp 178–179°. In the 100-MHz NMR spectrum (acetone-*d*<sub>6</sub>) the peak half-width of the C-9 proton (3.70 ppm) was 18.0 Hz, indicative of an axial proton.<sup>15</sup> Anal. (C<sub>20</sub>H<sub>30</sub>O<sub>3</sub>) C, H.

(±)-9-Nor-9α-hydroxyhexahydrocannabinol (11). To 0.03 g (0.0001 mol) of ketone 5 in 5 ml of dry THF under N<sub>2</sub> at –78° was added 1 ml of 0.5 M potassium tri-*sec*-butyl borohydride (0.0005 mol) from a syringe through a rubber septum. After stirring for 2 h at –78° a small amount of H<sub>2</sub>O was cautiously added. The aqueous layer was acidified with HCl and extracted with Et<sub>2</sub>O. The Et<sub>2</sub>O was washed with 5% NaHCO<sub>3</sub>, H<sub>2</sub>O, and brine and then dried (MgSO<sub>4</sub>). Evaporation gave a colorless, viscous liquid which was found by GC analysis to contain 98% of 11 and 2% or less of 9. Crystallization<sup>16</sup> from Et<sub>2</sub>O–ligroine gave 14 mg (47% yield) of white, crystalline 11, mp 138–140°. In the 100-MHz NMR spectrum (CDCl<sub>3</sub>) the peak half-width of the C-9 proton (4.25 ppm) was 8.0 Hz, indicative of an equatorial proton.<sup>15</sup> Anal. (C<sub>20</sub>H<sub>30</sub>O<sub>3</sub>) C, H.

(–)-9-Nor-9β-hydroxyhexahydrocannabinol (10) and (–)-9-Nor-9α-hydroxyhexahydrocannabinol (12). Using the same procedure as for 9 above, 2.0 g of ketone 6 gave approximately

2.0 g of a mixture of 10 and 12. Column chromatography over silica gel using acetone–ligroine gave initially 0.088 g of pure 12 (4.4% yield), followed by a mixture of 10 and 12, and then 0.4 g (20% yield) of pure 10. Both 10 and 12 were glassy substances which resisted attempts at crystallization. Also, the spectral and chromatographic properties of 10 and 12 were identical with their racemic counterparts 9 and 11, respectively.

**Acknowledgment.** The authors are indebted to Mrs. Louise Atwell for the analgesic testing.

## References and Notes

- (1) Presented in part at the 168th National Meeting of the American Chemical Society, Atlantic City, N.J., 1974.
- (2) Subsequent to the completion of this work, German Patent 2451-934 has appeared describing compounds of the same general class as those reported in this paper.
- (3) H. D. Christensen, R. I. Fruedenthal, J. T. Gidley, R. Rosenfeld, G. Boegli, L. Testino, D. R. Brine, C. G. Pitt, and M. E. Wall, *Science*, **172**, 165 (1971).
- (4) R. S. Wilson and E. L. May, *J. Med. Chem.*, **17**, 475 (1974).
- (5) R. S. Wilson and E. L. May, *J. Med. Chem.*, **18**, 700 (1975).
- (6) (a) H. C. Brown and S. Krishnamurthy, *J. Am. Chem. Soc.*, **94**, 7159 (1972); (b) C. A. Brown, *ibid.*, **95**, 4100 (1973).
- (7) B. R. Martin, W. L. Dewey, L. S. Harris, J. Beckner, R. S. Wilson, and E. L. May, *Pharmacol. Biochem. Behav.*, **3**, 849 (1975).
- (8) (a) H. Edery, Y. Grunfeld, Z. Ben-Zvi, and R. Mechoulam, *Ann. N.Y. Acad. Sci.*, **191**, 40 (1971); (b) G. Jones, R. G. Pertwee, E. W. Gill, W. D. M. Paton, I. M. Nilsson, M. Widman, and S. Agurell, *Biochem. Pharmacol.*, **23**, 439 (1974).
- (9) The authors thank Professor R. Mechoulam for bringing this to our attention.
- (10) R. Mechoulam, "Marihuana", Academic Press, New York and London, 1973.
- (11) B. R. Martin, W. L. Dewey, J. T. Earnhardt, M. D. Adams, L. S. Harris, R. S. Wilson, and E. L. May, unpublished results.
- (12) (a) N. B. Eddy and D. Leimbach, *J. Pharmacol. Exp. Ther.*, **107**, 385 (1953); (b) A. E. Jacobson and E. L. May, *J. Med. Chem.*, **8**, 563 (1965).
- (13) T. D. Perrine, L. Atwell, I. B. Tice, A. E. Jacobson, and E. L. May, *J. Pharm. Sci.*, **61**, 86 (1972).
- (14) J. C. Cradock, J. P. Davignon, C. L. Sitterst, and A. M. Guarino, *J. Pharm. Pharmacol.*, **25**, 345 (1973).
- (15) A. F. Casy, "PMR Spectroscopy in Medicinal and Biological Chemistry", Academic Press, New York and London, 1971, p 87.
- (16) Crystallization of the product from larger runs using up to 2.0 g of starting material was impeded by an oily by-product. This oil could be removed by distillation using a bath at 60° and high vacuum into a receptacle cooled in dry ice–Me<sub>2</sub>CO. Following chromatography of the residue over silica gel using ligroine (bp 30–60°)–Me<sub>2</sub>CO, pure 11 was obtained.